Table 1.
Clinical and demographical characteristics of the participants.
| Schizophrenia (SCZ) (n = 50) | Bipolar disorder (BPD) (n = 50) | Control participants (n = 50) | |
|---|---|---|---|
| Age (years) | 39.5 (8.4) | 40.5 (7.9) | 38.2 (8.5) |
| Sex (male/female) | 32/18 | 32/18 | 32/18 |
| Education (years) | 11.8 (5.7) | 11.7 (6.1) | 12.0 (6.3) |
| IQ | 98.4 (9.5) | 100.5 (9.0) | 101.7 (10.4) |
| Visual acuity (LogMAR) | 0.17 (0.09) | 0.19 (0.08) | 0.17 (0.04) |
| Duration of Illness (years) | 14.7 (8.3) | 14.9 (9.1) | – |
| WHODAS 2.0 | 21.3 (7.9) | 20.4 (6.8) | – |
| PANSS—P | 15.7 (5.2) | 16.8 (5.8) | – |
| PANSS—N* | 18.1 (4.8) | 15.4 (5.1) | – |
| PANSS—G | 40.2 (10.1) | 39.2 (12.1) | – |
| HAM-D | 10.3 (5.8) | 10.9 (7.5) | – |
| YMRS | 4.5 (2.1) | 4.0 (2.9) | – |
| Chlorpromazine (CPZE)-equivalent antipsychotic dose (mg/day) | 326.3 (179.4) | 328.7 (215.5) | – |
Data are mean (standard deviation) except the sex ratio. PANSS, Positive and Negative Syndrome Scale; HAM-D, Hamilton Rating Scale for Depression; YMRS, Young Mania Rating Scale; WHODAS 2.0, WHO Disability Assessment Schedule 2.0; *p < 0.05 (two-tailed t-test).